FDA to hold meeting on CAD fetal monitors

The FDA is seeking feedback on evaluating and improving the effectiveness of fetal monitors that use computer-aided detection (CAD) technology.

To evaluate the technology, the agency is holding a free all-day workshop on the subject on Nov. 10 at its Silver Spring, Md., campus.

Attendees will discuss how to identify and differentiate the various categories of the devices and the corresponding levels of evidence needed to validate them. Participants also will discuss how current databases might be used to verify and validate algorithms for the devices.

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.